摘要
Dear Editor,Hepatoblastoma(HB)is a predominant hepatic neoplasm that develops in children from 0 to 4 years of age at the rate of 2.16 per 1,000,000.It originates from abnormal differentiation of hepatocyte precursors(hepatoblasts)during embryogenesis(Sumazin et al.,2017).Approximately 20%of children with HB have metastasis in lung at diagnosis,which indicates poor prognosis(Angelico et al.,2019).While surgery in combination of chemotherapy and/or metastasectomy is the most popular therapy,relapse happens in a significant portion of HB patients(Zhang et al.,2021).Therefore,novel and less aggressive therapies targeting the pathogenesis of HB should be explored to prolong patients’s disease-free survival as well as to improve their quality of life.
